Alder Biopharmaceuticals Inc. Garners $40,000,000 Series C Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c6f35ab3-19a1-4cde-825f-3e687584c883&Preview=1 -
Date
1/11/2008 -
Company Name
Alder Biopharmaceuticals Inc. -
Mailing Address
11804 North Creek Parkway South Bothell, WA 98011 -
Company Description
Alder Biopharmaceuticals uniquely identifies, develops, and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder’s management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics. -
Website
http://www.alderbio.com -
Transaction Type
Venture Equity -
Transaction Amount
$40,000,000 -
Transaction Round
Series C -
Proceeds Purposes
Alder plans to use the financing to advance its lead programs through human clinical trials and to continue to advance its proprietary Mab Xpress yeast antibody production technology. -
M&A Terms
-
Venture Investor
Delphi Ventures -
Venture Investor
TPG – Texas Pacific Group Ventures -
Venture Investor
Sevin Rosen Funds -
Venture Investor
Ventures West -
Venture Investor
H.I.G. Ventures -
Venture Investor
WRF Capital
